Toggle Nav
Close
  • Menu
  • Setting

Tyrosine Kinase

Tyrosine kinase is a large group of proteins regulates the function of cell growth, differentiation, motility, cytoskeletal rearrangement and adhesion etc. They activate the target protein through transfer of phosphate from ATP to the hydroxyl group of a target protein tyrosine. Transmembrane receptor kinases and non-receptor cytoplasmic kinases are two main categories of the tyrosine kinases.

Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.

Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.

10 Items

per page
  1. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  2. Masitinib (AB1010)
    A2942 Masitinib (AB1010)
    Target: PDGFR|c-Kit|Lyn
    Summary: Tyrosine kinase inhibitor, potent and selective
      ≥24.95 mg/mL
  3. Dovitinib (TKI-258, CHIR-258)
    A2168 Dovitinib (TKI-258, CHIR-258)
     2 Citation
    Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: Multitargeted RTK inhibitor
      insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
  4. Axitinib (AG 013736)
    A8370 Axitinib (AG 013736)
     1 Citation
    Target: VEGFR|PDGFR|c-Kit
    Summary: VEGFR1/ c-Kit inhibitor
      insoluble in H2O; ≥19.3 mg/mL
  5. Telatinib (BAY 57-9352)
    A8550 Telatinib (BAY 57-9352)
    Target: VEGFR|PDGFR|c-Kit
    Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor
      insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
  6. Pexidartinib (PLX3397)
    B5854 Pexidartinib (PLX3397)
     3 Citation
    Target: FLT3|c-Kit|CSF1R
    Summary: CSF-1R inhibitor
      insoluble in EtOH; insoluble in H2O; ≥20.9 mg/mL
  7. Dovitinib (TKI258) Lactate
    B5953 Dovitinib (TKI258) Lactate
    Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).
      insoluble in EtOH; ≥10.62 mg/mL
  8. Imatinib (STI571)
    B2171 Imatinib (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Protein-tyrosine kinase inhibitor
      ≥24.68 mg/mL
  9. Pazopanib (GW-786034)
    A3022 Pazopanib (GW-786034)
    Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
  10. Regorafenib hydrochloride
    A3750 Regorafenib hydrochloride
    Target: Raf|VEGFR|PDGFR|c-Kit|c-RET
    Summary: Tyrosine kinase inhibitor
      ≥25.95 mg/mL

10 Items

per page